Edition:
India

Imv Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

3.76CAD
10:29pm IST
Change (% chg)

$-0.12 (-3.09%)
Prev Close
$3.88
Open
$3.80
Day's High
$3.94
Day's Low
$3.60
Volume
110,291
Avg. Vol
59,153
52-wk High
$8.49
52-wk Low
$3.60

Latest Key Developments (Source: Significant Developments)

Imv Inc Reports Results From Mid-Stage Trial Testing Its Experimental Lymphoma Treatment
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Imv Inc ::NEW PHASE 2 CLINICAL TRIAL RESULTS CONTINUE TO DEMONSTRATE POTENTIAL CLINICAL BENEFIT OF IMV’S DPX-SURVIVAC IN COMBINATION WITH MERCK’S KEYTRUDA IN PATIENTS WITH DLBCL.IMV INC - COMPLETE RADIOLOGIC RESPONSES LINKED TO T CELL ACTIVITY OBSERVED IN TWO OF FIRST SIX EVALUABLE PATIENTS.IMV - AT FIRST "ON TREATMENT" ASSESSMENT, FIVE OF FIRST SIX PATIENTS DEMONSTRATED CLINICAL BENEFIT, INCLUDING FOUR PATIENTS WITH TUMOR REGRESSIONS.IMV INC - TREATMENT COMBINATION APPEARS TO BE WELL-TOLERATED WITH ONLY 2 SERIOUS ADVERSE EVENTS RELATED TO TREATMENT.  Full Article

IMV Inc. Announces Pricing Of Public Offering
Friday, 1 Mar 2019 

March 1 (Reuters) - Imv Inc ::IMV INC ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS OFFERING OF 4.90 MILLION COMMON SHARES PRICED AT C$5.45PER SHARE.INTENDS TO USE NET PROCEEDS OF OFFERING TO ACCELERATE DEVELOPMENT OF DPX-SURVIVAC IN COMBINATION WITH KEYTRUDA.  Full Article

IMV Inc Reaches Multiple Milestones In Advanced Ovarian Cancer Clinical Trial
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Imv Inc ::IMV INC. REACHES MULTIPLE MILESTONES IN ADVANCED OVARIAN CANCER CLINICAL TRIAL.IMV INC - EXPECTS TO RELEASE TOPLINE DATA FROM PHASE 1B ARMS OF STUDY BY END OF 2018.  Full Article

IMV Inc Reports Q1 Loss Per Share $0.7
Tuesday, 15 May 2018 

May 14 (Reuters) - Imv Inc ::IMV INC. (FORMERLY IMMUNOVACCINE INC.) ANNOUNCES Q1 2018 FINANCIAL RESULTS.IMV INC - QTRLY LOSS PER SHARE $0.7.  Full Article

Immunovaccine And Incyte Expand Clinical Collaboration
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER.IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTE'S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE.IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL.IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Immunovaccine reports qtrly loss per share of ‍$0.02​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share ‍$0.02​.  Full Article

Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.  Full Article